Effects of long-term administration of the antiepileptic drug - sodium valproate upon the ultrastructure of hepatocytes in rats

Experimental and Toxicologic Pathology

Volumn 49, Issue 3-4, 1997, Pages 225-232

  Sobaniec Łotowska, Maria E ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Antiepileptic drug; Hepatocyte; Liver; Microvesicular fatty change; Sodium valproate; Toxic effects

Indexed keywords

ANTICONVULSIVE AGENT; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; INTRAGASTRIC DRUG ADMINISTRATION; LIVER CELL; LIVER MITOCHONDRION; LIVER TOXICITY; LONG TERM EXPOSURE; NONHUMAN; PEROXISOME; RAT; ULTRASTRUCTURE;

ANIMALIA;

EID: 0030767536     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0940-2993(97)80015-2     Document Type: Article

References (46)

1. BACHMAN DS: Use of valproic acid in treatment of infantile spasms. Arch Neurol 1982; 39: 49-52.
2. BAUER J, ELGER CE: Intoxikationen und Enzephalopathien unter Valproinsäuretherapie. In: KRAMER G, LAUB M (eds.): Vaproinsäure. Springer Berlin 1992; pp. 252-258.
3. BECK-MANNAGETTA G: Klinische Aspecte der Teratogenität von Valproinsäure und Therapie in der Schwangerschaft. In: KRÄMER G, LAUB M (eds): Valproinsäure. Springer Berlin 1992; pp. 298-303.
4. BEGHI E, BIZZI A, CODEGONI MA, et al.: Valproate carinitine metabolism, and biochemical indicators of liver function. Epilepsia 1991; 31: 346-352.
5. BJORGE SM, BAILLIE TA: Studies on the beta-oxidation of valproic acid in rat liver mitochondrial preparations. Drug Metab Dispos 1991; 19: 823-829.
6. BOJES HK, THURMAN RG: Peroxisomal proliferators inhibit acyl CoA synthetase and stimulate protein kinase C in vivo. Toxicol Appl Pharmacol 1994; 126: 233-239.
7. CAMPOSTRINI R, ZACCARTA G, ROSSI L, et al.: Valproate induced hyperammonaemia in two epileptic identical twins. J Neurol 1985; 235: 167-168.
8. COULTER DL, ALLEN RJ: Secondary hyperammonaemia: as possible mechanism for valproate encephalopathy. Lancet 1980, 1: 1310-1311.
9. DAVIS R, PETERS DH, MCTAVISH D: Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994; 47: 332-372.
10. DREIFUSS FE, LANGER DH, MOLINE KA, et al.: Valproic acid hepatic fatalities. II. US experience sice 1984. Neurology 1989; 39: 201-207.
11. GRAF R, GOSSRAU R, MERKER HJ, et al.: Enzyme cytochemistry combined with electron microscopy, pharmacokinetics, and clinical chemistry for the evaluation of the effects of steady-state valproic concentrations on the mouse. Histochemistry 1985; 83: 347-358.
12. HORIE S, SUGA T: Enhancement of perixosimal beta-oxidation in the liver of rats and mice treated with valproic acid. Brochem Pharmacol 1985; 34: 1357-1362.
13. IMLER M, WARIER JM, MARESCAUX C: Valproate de sodium, hyperammoniemie et encephalopathie hepatique. Gastroenterol Clin Biol 1982; 6: 1042-1050.
14. KESTERSTON J, GRANNEMAN RG, MACHINIST J: The hepatotoxicity of valproic acid and its metabolites in rats. I Toxicologic, biochemical and histopathologic studies. Hepatology 1984; 4: 1143-1152.
15. LAUB MC: Einfluß von Valproinsäure auf Fettstoffwechsel und Carnitin. KRÄMER G, LAUB M (eds): Valproinsäure Springer Berlin 1992; pp. 225-237.
16. LEWIS JH, ZIMMERMAN HJ, GARRET CT, et al.: Valproate - induced hepatic steatogenesis in rats. Hepatology 1982; 2: 870-873.
17. LØYNING Y, JOHANNESSEN SJ, RITLAND S, et al.: Cases of serious/fatal hepatotoxicity due to valproate: recommended monitoring schame and preliminary results. In: OXLES J, JANZ D, MEINARIDI H (eds.): Antiepileptic therapy: chronic toxicity of antiepileptic drugs. Raven Press New York 1983; pp. 47-60.
18. LÖSCHER W: Valproic acid. In: FREY HH, JANZ D (eds.): Antiepileptic drugs. Handbook of experimental pharmacology. Springer Berlin 1985; Vol 74 pp. 507-536.
19. MATHIS RK, LINDAH JA, FREESE DK, et al.: Valproic acid and hepatocyte failure in children. Pediatr Res 1979, 13: 527 (abstr.).
20. MCELROY S, KECK PE JR, POPE HG JR: Sodium valproate: Its use in primary psychiatric disorders. J Clin Psychopharmacol 1987, 7: 16-24.
21. NAU H, HELGE H, LUCK W: Valproic acid in the perinatal period: Decreased maternal serum protein binding results in fetal accumulation and neonatal displacement of the drug and some metabilites. J Pediatrics 1984; 1: 627-634.
22. NAU H, MERKER HJ, BRENDEL K, et al.: Disposition embryotoxicity and teratogenicity of valproic acid in the mouse as related to man. In: LEVY RH, PITICK WH, EICHELBAUM M, MEIJER J (eds.): Metabolism of antiepileptic drugs. Raven Press New York 1984; pp. 85-104.
23. OHTANI Y, ENDO F, MATSUDA I: Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 1982; 101: 782-785.
24. OLSON MJ, HANDLER JA, THURMAN RG: Mechanism of zone - specific hepatic steatosis caused by valproic: Inhibition of ketogenesis in periportal regions of the liver lobule. Mol Pharmacol 1986; 30: 520-525.
25. PONCHAUT S, DRAYE JP, VEITCH K, et al.: Influence of chronic administration of valproate on ultrastructure and enzyme content of perixisomes in rat liver and kidney. Oxidation of valproate by liver peroxisomes. Biochem Pharmacol 1991; 41: 1419-1428.
26. PUZYŃSKI S, KLOSIEWICZ L: Valproic acide amide in the treatment of affective and schizoaffective disorders. J Affect Disord 1984; 6: 1115-1121.
27. ROCHEL M, EHRENTHAL W: Haematological side effects of valproic acid. In: OXLEY J, JANZ D, MEINARDI H (eds.). Antiepileptict therapy: chronic toxicity of antiepileptic drugs. Raven Press New York 1983; pp. 101-105.
28. SCHEFFNER D, KONIG S, RAUTERBERG-RULAND I, et al.: Fatal liver failure in 16 children with valproate therapy. Epilepsia 1988, 29: 530-542.
29. SCHÖNDIENST M, WOLF P: Zur Möglichkeit neurotoxischer Spätwirkungen durch Valproinsäure. In: KRÄMER G, LAUB M (eds.): Valproinsäure. Springer Berlin 1992; pp. 259-265.
30. SOBANIEC W: Assessment of undesirable action of sodium valproate in children treatment chronically due to epilepsy. Neurosciences 1991; 17: 281-288.
31. SOBANIEC W, JANKOWICZ E, CZERWIŃSKA-CIECHAN K: Detailed monitoring of valproic acid and phenobarbital acid and phenobarbital in the treatment of epilepsy in children (in Polish). Neur Neurochir Pol 1988; 12: 413-420.
32. SOBANIEC W, JANKOWICZ E, SOBANJEC-ŁOTOWSKA M: The effect of valproic acid on the morphology of the rat cerebellum and brain stem. Neuropat Pol 1989, 27: 137-150.
33. SOBANIEC-ŁOTOWSKA M: Hepatic encephalopathy evoked by long-term administration of sodium valproate (VPA). Ultrastructure of hepatocyte, capillaries and neuroglial cells in dentate nucleus of cerebellum. Falk Symposium No. 79. Portal Hypertension. Juni 17-19. 1994 Freiburg/Breisgau, 1994a; 30 (abst).
34. SOBANIEC-ŁOTOWSKA M: Ultrastructure of capillaries and neuroglial cells in the cerebellar cortex in rats given chronically sodium valproate. Eur J Pharmaceutical Sci 1994b; 2: 164.
35. SOBANIEC-ŁTOWSKA M, SOBANIEC W: Effect of chronically administration sodium valproate on the morphology of the rat brain hemispheres. Neuropat Pol 1993a, 31: 153-162.
36. SOBANIEC-ŁOTOWSKA M, SOBANIEC W: Long-term sodium valproate induced encephalopathy. Pathology Res Pract 1993b; 189 (suppl.): 184.
37. SOBANIEC-ŁOTOWSKA M, SOBANIEC W: Hepatocyte ultrastructure, certain enzyme parameters and blood serum ammonia in rats given chronically and acutely sodium valproate (VPA). Falk Symposium No 75 Cholestatic Liver Diseases. April 22-23. 1994c, Maastricht, 2 (abstr.).
38. SOBANIEC- ŁOTOWSKA M, SOBANIEC W: Studies on the rat liver morphology during chronic and acute administration of sodium valproate. Falk Symposium No 79, Portal Hypertension June 17-19. 1994, Freiburg/Breisgau, 1994d; 12 (abstr.).
39. SOBANIEC-ŁOTOWSKA M, SOBANIEC H: An ultrastructural study of the rat hepatic sinusoidal cells - endothelial cells and Kupffer cells during chronic experimental administration of the antiepileptic drug - sodium valproate. Falk Symposium No 83. Advances in Hepatobiliary and Pancreatic Diseases. April 7-8. 1995. Bolzano, 1995a; 20 (abstr.).
40. SOBANIEC-ŁOTOWSKA M, SOBANIEC W: Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats. A transmission electron microscopic study of capillaries in the cerebellar cortex. Exp Toxic Pathol 1995b; 47 (in press).
41. SOBANIEC-ŁOTOWSKA M, SOBANIEC W, KULAK W: Rat liver pathomorphology during prolonged sodium valproate administration. Mat Med Pol 1993; 25: 9-12.
42. SUCHY FJ, BALISTRERI WF, BUCHINO JJ, et al.: Acute hepatic failure associated with the use of sodium valproate. Report of two fatal cases. N Engl J Med 1979; 300: 962-966.
43. THURSTON JH, HAUHART RE: Amelioration of adverse effects of valproic acid on ketogenesis and liver Coenyzme A. Metabolism by cotreatment with panthothenate and carnitine in developing mice: possible clinical significance. Pediatr Res 1992; 31: 419-423.
44. VAMECQ J, VALLEE L, FONTAINE M, et al.: CoA esters of valproinc acid and related metabolites and oxidized in peroxisomes through pathway distinct from peroxisomal fatty and bile acyl-CoA beta-oxidation. FEBS-Lett 1993; 322: 95-100.
45. WARE S, MILLWARD-SADLER GH: Acute liver disease associated with sodium valproate. Lancet 1980; 2: 1110-1113.
46. WYLLIE E, WYLLIE R, CRUSE RP, et al.: Pancreatitis associated with valproic acid therapy. Am J Dis Child 1984; 138: 912-914.